PMID- 37458962
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20230825
IS  - 2520-8721 (Electronic)
IS  - 1109-3099 (Linking)
VI  - 22
IP  - 3
DP  - 2023 Sep
TI  - An evaluation of both serum Klotho/FGF-23 and apelin-13 for detection of diabetic 
      nephropathy.
PG  - 413-423
LID - 10.1007/s42000-023-00464-4 [doi]
AB  - PURPOSE: The aim of our study is to evaluate whether serum Klotho/FGF-23 and 
      apelin-13 can be used as new biomarkers for detection of development of 
      nephropathy. METHODS: In this cross-sectional study, 88 type 2 diabetes mellitus 
      (T2DM) patients and 38 healthy controls were included. The mean duration of T2DM 
      was 11.4 +/- 9.7 years. T2DM individuals were categorized into two groups as group 
      1 with e-GFR < 60 mL/min/1.73 m(2) and group 2 with e-GFR > 60 mL/min/1.73 m(2). 
      They were also divided into two groups according to their 24 h urine albumin 
      levels, classifying them as follows: normoalbuminuria if less than 30 mg/day and 
      albuminuria if more than 30 mg/day. RESULTS: Mean serum Klotho levels in the T2DM 
      group were observed to be significantly higher than in the control group. Serum 
      apelin-13 levels were observed to be significantly lower in the T2DM group 
      compared to the control group (p < 0.001). In the diabetic group, apelin-13 
      levels were positively correlated with age, waist circumference, and albuminuria 
      while they were negatively correlated with e-GFR. Apelin-13 levels were seen to 
      be significantly higher in group 1 (p < 0.001). CONCLUSION: Apelin-13 levels were 
      found to be significantly higher in individuals with diabetic nephropathy than in 
      those without diabetic nephropathy. In the diabetic group, a significant 
      relationship was detected between apelin-13 levels and albumin excretion. Based 
      on these findings, we consider that serum Klotho and apelin-13 levels may have a 
      protective effect on diabetic nephropathy and can additionally be used as a 
      biomarker to predict diabetic nephropathy.
CI  - (c) 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
FAU - Ozdemir, Nilufer
AU  - Ozdemir N
AUID- ORCID: 0000-0002-0719-988X
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Manisa Celal 
      Bayar University, Manisa, Turkey. nozdemirkutbay@hotmail.com.
FAU - Toraman, Aysun
AU  - Toraman A
AD  - Department of Nephrology, Faculty of Medicine, Manisa Celal Bayar University, 
      Manisa, Turkey.
FAU - Taneli, Fatma
AU  - Taneli F
AD  - Department of Clinical Biochemistry, Faculty of Medicine, Manisa Celal Bayar 
      University, Manisa, Turkey.
FAU - Yurekli, Banu Sarer
AU  - Yurekli BS
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Ege University, 
      Izmir, Turkey.
FAU - Hekimsoy, Zeliha
AU  - Hekimsoy Z
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Manisa Celal 
      Bayar University, Manisa, Turkey.
LA  - eng
GR  - 2018-245/Manisa Celal Bayar Universitesi/
PT  - Journal Article
DEP - 20230717
PL  - Switzerland
TA  - Hormones (Athens)
JT  - Hormones (Athens, Greece)
JID - 101142469
RN  - 0 (apelin-13 peptide)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - 0 (Albumins)
RN  - 0 (Apelin)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Diabetic Nephropathies/diagnosis
MH  - *Diabetes Mellitus, Type 2
MH  - Glucuronidase
MH  - Albuminuria/diagnosis/urine
MH  - Cross-Sectional Studies
MH  - Albumins
MH  - Apelin
MH  - Biomarkers
OTO - NOTNLM
OT  - Apelin-13
OT  - Diabetic nephropathy
OT  - Serum Klotho/FGF-23
EDAT- 2023/07/17 15:08
MHDA- 2023/08/25 06:43
CRDT- 2023/07/17 11:14
PHST- 2022/11/23 00:00 [received]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/08/25 06:43 [medline]
PHST- 2023/07/17 15:08 [pubmed]
PHST- 2023/07/17 11:14 [entrez]
AID - 10.1007/s42000-023-00464-4 [pii]
AID - 10.1007/s42000-023-00464-4 [doi]
PST - ppublish
SO  - Hormones (Athens). 2023 Sep;22(3):413-423. doi: 10.1007/s42000-023-00464-4. Epub 
      2023 Jul 17.